GlycoMimetics, Inc. (NASDAQ:GLYC) announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. GlycoMimetics, Inc. (NASDAQ:GLYC) belongs to Healthcare sector. Its net profit margin is -73.70% and weekly performance is 0.83%. On last trading day company shares ended up $7.25. GlycoMimetics, Inc. (NASDAQ:GLYC) distance from 50-day simple moving average (SMA50) is -7.81%.
Altria Group (NYSE:MO) has earned a “BBB” credit rating from analysts at Morningstar. The investment research firm’s “BBB” rating suggests that the company is a moderate default risk. They also gave their stock a two star rating. Altria Group Inc. (NYSE:MO) shares advanced 1.58% in last trading session and ended the day at $46.19. MO Gross Margin is 41.30% and its return on assets is 12.40%. Altria Group Inc. (NYSE:MO) quarterly performance is 9.69%.
Science Applications International Corp (NASDAQ:SAIC) Insider Douglas Martin Wagoner sold 6,902 shares of Science Applications International Corp stock on the open market in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $46.21, for a total transaction of $318,941.42. Following the sale, the insider now directly owns 50,418 shares of the company’s stock, valued at approximately $2,329,816. On 03 October, Science Applications International Corporation (NYSE:SAIC) shares advanced 2.04% and was closed at $46.53. SAIC EPS growth in last 5 year was 0.00%. Science Applications International Corporation (NYSE:SAIC) year to date (YTD) performance is 43.74%.
On Sept. 29, Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), announced the presentation of clinical data from an ongoing Phase 1 clinical study for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound, in patients with advanced solid tumors. Data presented in patients with chemotherapy refractory, castrate-resistant prostate cancer (CRPC) treated with single-agent Selinexor showed a 60% disease control rate with maximum prostate-specific antigen (PSA) reduction ranging from 27% to 60% and duration of treatment up to 502 days. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) ended the last trading day at $33.09. Company weekly volatility is calculated as 8.65% and price to cash ratio as 8.17. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) showed a weekly performance of -21.40%.
On Sep 30, Selectica, Inc. (NASDAQ:SLTC) introduced configurable contract approval workflows for Iasta SmartSource Contract Management. Automating contract approval processes are proven to demonstrate: Reduced contract-cycle time ; Contract and supplier risk avoidance; Enhanced employee productivity; Detailed audit trail and Identification of inefficiencies in approval processes. Selectica, Inc. (NASDAQ:SLTC) shares moved down -5.84% in last trading session and ended the day at $5.64. SLTC Gross Margin is 42.10% and its return on assets is -65.60%. Selectica, Inc. (NASDAQ:SLTC) quarterly performance is -14.67%.